黄超兰
北京大学医学部精准医疗多组学研究中心，主任
黄超兰教授2003年在香港大学取得博士，专业攻读质谱机理，研究多肽的质谱气相热动学及其裂解途径。2005-2007年，为美国斯克里普斯研究所(The Scripps Research Institute ) John R Yates教授实验室访问学者、博士后研究员，开始从事基于质谱的蛋白质组学前沿新技术和方法的研究开发工作。2007年，留任斯克里普斯研究所。2013年1月受中科院人才招聘回国，参与中科院国家蛋白质科学中心的建设。2014年获选为“中科院引进杰出技术人才”。2017年被引进北大医学部，组建北京大学医学部精准医疗多组学研究中心，担任中心主任。黄教授从事质谱技术及基于质谱的蛋白质组学在基础研究和临床研究的方法学开发。发表研究论文65篇（其中归国后2015-2017年发表25篇），包括 Science, Nature Method, Nature Communication，PLoS Biology, PNAS and Molecular Cell，EMBOJ等，H-指数为28。
Guan Zheng received BSc. and MSc. degree from Peking University (Pharmaceutical Science). Then he started working at Centre for Human Drug Research (CHDR, Leiden, the Netherlands) and served as a PK/PD modeler and a project leader. He mainly focused on PK/PD modeling & simulation and early phase clinical trials. Zheng had PhD. training of clinical pharmacology in Leiden University Medical Center (LUMC) since 2012. Zheng joined Johnson & Johnson China R&D clinical pharmacology team from 2013 to 2018 working in multiple disease areas. From early 2018, Zheng joined Deep Intelligent Pharma as a founding partner. Zheng has authored and coauthored 15+ publications in pharmaceutical science.
Shuhei NARITA
日本CMIC有限公司公司商务拓展副经理
There are many factors in the manufacturing process for large molecular drugs, and it is difficult to control them. In addition, it is difficult to recognize changes in state or substances during manufacturing. By using AI, if we can control manufacturing and control quality, development of more large molecular drugs will be accelerated.
This session will explain the future image of large molecular drug development focusing on the CMC area that AI is likely to utilize.
Joined CMIC Pharma Science Co., Ltd. as of 2000. and experienced physicochemical analysis, analysis using microorganisms and cells, and biopharmaceutical analysis.
Since 2011, experienced in biopharmaceutical group, GMP release tests of biopharmaceuticals, Transfer in overseas client labs, Global Transfer in Sapporo lab.
Experience of Global QA audit, FDA audit, PMDA audit related to biopharmaceuticals and microorganisms.
CMIC Pharma Science Co., Ltd Business Solution Division Global Solution since October 2016
Transferred to CMIC HOLDINGS Co., Ltd. from October 2018
